does medicaid cover glp-1 in ny Coverage of and Spending on GLP-1s State-by-State Divide Over GLP-1 Medicaid

Current Medical Research and Opinion

The cagrilintide dosing protocols are still being established, but the mechanism of action, targeting amylin receptors for appetite regulation, offers a novel pathway distinct from GLP-1 agonism

Although Ozempic, Mounjaro, and Rybelsus are not FDA-approved for obesity treatment, they are included in the analysis due to the high number of patients with an obesity diagnosis using these products compared to other FDA-approved Type 2 diabetes GLP-1 agonists

[PubMed] [Google Scholar] 12.Ui M., Claus T.H., Exton J.H., Park C.R

Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension